CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands		Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2021		$ 46	$ 368,852	$ (374,934)	$ (6,036)
Beginning balance (in shares) at Dec. 31, 2021	[1]	45,556,647
Share-based compensation related to stock options			149		149
Share-based compensation related to restricted stock awards			687		687
Share-based compensation related to restricted stock awards (in shares)	[1]	759,482
Net loss for the period				(2,286)	(2,286)
Ending balance at Mar. 31, 2022		$ 46	369,688	(377,220)	(7,486)
Ending balance (in shares) at Mar. 31, 2022	[1]	46,316,129
Beginning balance at Dec. 31, 2022		$ 54	379,167	(389,861)	(10,640)
Beginning balance (in shares) at Dec. 31, 2022	[1]	53,790,167
Issuance of common stock under the Sales Agreement, net		$ 8	14,225		14,233
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	8,212,482
Share-based compensation related to stock options			453		453
Share-based compensation related to restricted stock awards			93		93
Net loss for the period				(3,131)	(3,131)
Ending balance at Mar. 31, 2023		$ 62	$ 393,938	$ (392,992)	$ 1,008
Ending balance (in shares) at Mar. 31, 2023	[1]	62,002,649

[1] Common stock, $0.001 par value; Authorized – as of March 31, 2023 and 2022 – 144,000,000 and 120,000,000 shares, respectively.